Marinus Pharmaceuticals to Present at Upcoming Investor Conferences

Rhea-AI Summary

Marinus Pharmaceuticals (Nasdaq: MRNS) announced its participation in several upcoming conferences aimed at advancing innovative therapeutics for seizure disorders. Key presentations include the SVB Securities Global Biopharma Conference on February 15 at 2:20 p.m. E.T., the Cowen 43rd Annual Health Care Conference on March 6 at 12:50 p.m. E.T., and the Oppenheimer 33rd Annual Healthcare Conference on March 14 at 4:00 p.m. E.T.. Webcast replays will be available post-event. Marinus is known for its FDA-approved product, ZTALMY (ganaxolone), targeting seizures associated with CDKL5 deficiency disorder.

RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present and participate during the following conferences in February and March.

• SVB Securities Global Biopharma Conference (virtual)
  • February 15 at 2:20 p.m. E.T.

• Cowen 43rd Annual Health Care Conference in Boston, MA
  • March 6 at 12:50 p.m. E.T.

• Oppenheimer 33rd Annual Healthcare Conference (virtual)
  • March 14 at 4:00 p.m. E.T.

Links to the events can be accessed on the Investors & Media page of Marinus’ website at ir.marinuspharma.com/events-and-presentations. A replay of the webcasts will be available approximately two hours after the completion of the events and will be archived for up to 90 days.

About Marinus Pharmaceuticals

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s commercial product, ZTALMY^® (ganaxolone) oral suspension CV, has been approved by the U.S. FDA for the treatment of seizures associated with CDKL5 deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other rare seizure disorders, including in Phase 3 trials in tuberous sclerosis complex and refractory status epilepticus. Ganaxolone is a neuroactive steroid GABA_A receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. It is being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information visit www.marinuspharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005159/en/

Company Contact

Sasha Damouni Ellis

Senior Vice President, Corporate Affairs & Investor Relations

Marinus Pharmaceuticals, Inc.

sdamouni@marinuspharma.com

Source: Marinus Pharmaceuticals

FAQ

What events is Marinus Pharmaceuticals participating in February and March 2023?

Marinus Pharmaceuticals will participate in the SVB Securities Global Biopharma Conference on February 15, the Cowen 43rd Annual Health Care Conference on March 6, and the Oppenheimer 33rd Annual Healthcare Conference on March 14.

When will Marinus Pharmaceuticals present at the SVB Securities Global Biopharma Conference?

Marinus Pharmaceuticals is scheduled to present at the SVB Securities Global Biopharma Conference on February 15, 2023, at 2:20 p.m. E.T.

What is the significance of ZTALMY for Marinus Pharmaceuticals?

ZTALMY (ganaxolone) is Marinus Pharmaceuticals' approved product for treating seizures associated with CDKL5 deficiency disorder, and its potential is being explored in other seizure disorders.

How can I access the webcasts of Marinus Pharmaceuticals' conference presentations?

Webcasts of Marinus Pharmaceuticals' conference presentations will be available approximately two hours after the events on their Investors & Media page.